How to integrate surgery and targeted therapy with biologics for the treatment of hidradenitis suppurativa: Delphi consensus statements from an Italian expert panel
Annamaria Offidani,Angelo Valerio Marzano,Ketty Peris,Elisa Molinelli,Vincenzo Bettoli,Cristina Magnoni,Luca Vaienti,Giovanni Pappagallo,Paolo Amerio,Laura Atzori,Anna Balato,Luca Bianchi,Maria Rita Bongiorno,Federico Contedini,Paolo Dapavo,Giovanni Di Benedetto,Valentina Dini,Massimo Donini,Gabriella Fabbrocini,Luca Fania,Caterina Foti,Alessandro Gatti,Claudio Guarneri,Giovanna Malara,Marco Manfredini,Pietro Morrone,Luigi Naldi,Aurora Parodi,Concetta Potenza,Sandra Schianchi,Luca Stingeni,Emanuele Trovato,Fabrizio Vaira,Mario Valenti,Marina Venturini,Andrea Chiricozzi,Francesca Prignano
DOI: https://doi.org/10.1159/000539264
2024-07-18
Dermatology
Abstract:Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by recurrent and painful nodules and abscesses in intertriginous skin areas, which can progress to sinus tract formation, tissue destruction, and scarring. HS is highly debilitating and severely impairs the psychological well-being and quality of life of patients. The therapeutic approach to HS is based on medical therapy and surgery. First-line medical therapy includes topical antibiotics, systemic antibiotics, and biologics. Main surgical procedures include deroofing, local excision, and wide local excision. Despite the availability of multiple therapeutic options, the rates of disease recurrence and progression continue to be high. In recent years, the possibility of combining biologic therapy and surgery has raised considerable interest. In a clinical trial, the perioperative use of adalimumab has been associated with greater response rates and improved inflammatory load and pain, with no increased risk of postoperative infectious complications. However, several practical aspects of combined biologic therapy and surgery are poorly defined. In June 2022, nine Italian HS experts convened to address issues related to the integration of biologic therapy and surgery in clinical practice. To this purpose, the experts identified ten areas of interest based on published evidence and personal experience: 1) patient profiling (diagnostic criteria, disease severity classification, assessment of response to treatment, patient-reported outcomes, comorbidities); 2) tailoring surgery to HS characteristics; 3) wide local excision; 4) pre-surgery biologic treatment; 5) concomitant biologic and surgical treatments; 6) pre- and post-surgery management; 7) antibiotic systemic therapy; 8) biologic therapy after radical surgery; 9) management of adverse events to biologics; 10) management of postoperative infectious complications. Consensus between experts was reached using the Estimate-Talk-Estimate method (Delphi Method). The statements were subsequently presented to a panel of 27 HS experts from across Italy, and their agreement was assessed using the UCLA Appropriateness Method. This article presents and discusses the consensus statements.
dermatology